


FIG. 1

12-9A CHIMERIC ANTIBODIES; DAY 2



CHIMERIC mAb CAPTURE BINDING OF C1A TO CHIMERIC mAb

FIG. 2




FIG. 3




FIG. 4




FIG. 6




FIG. 7

VARIABLE LIGHT CHAIN		CDR 1	CDR 2	CDR 3
ANTIBODY				
1771	LSSQSLLDSDGKTF LN	LVSKLDS	WQGTHFPYT	
12-9 (C1FA)	KSSQSVLYSSNQKNYLA	WASTRES	HQYLSST	
13-2	KSSQSVLYSSNQKNYLA	WASTRES	HQYLSST	
35-006	KSSQSVLYSSNQKNYLA	WASTRES	HQYLSST	
35-220	RSSQSVLYSSNQKNYLA	WASTRES	HQYLSST	
CONSENSUS	KSSQSVLYSSNQKNYLA	WASTRES	HQYLSST	H

VARIABLE LIGHT CHAIN		CDR1	CDR2	CDR3
ANTIBODY				
1771	SGFSWH	YIHYSGSTDCNP SLKS	MPDS	
12-9 (C1FA)	RYSVH	MIWGGGNTDYN SALKS	KGEFY YGYDGFVY	
13-2	RYNIH	MIWGGGNTDYN SALKS	AYYGN SWFAY	
35-006	RYSVH	MIWGGGNTDYN SALKS	RLWYFDV	
35-220	RYSVH	MIWGGGNTDYN SALKS	AYYGN SWFAY	
CONSENSUS	RYSVH NI	MIWGGGNTDYN SALKS ES	AYYGN SWFA * * * Y KGEFY YGYD RLWYFDV	

FIG. 8

10035032 . 043 902